AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2893417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg IV lormetazepam
Number of subjects: 30
Study 2893417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg IV Ro 15-1788
Number of subjects: 30
Study 2893417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2893417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 30
Study 2893417 — intervention group
Group type: COMPARATOR
Intervention: Drug-free control group
Number of subjects: 30
Study 28563995 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACS BT
Number of subjects: 343
Study 28563995 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACS TT
Number of subjects: 343
Study 28563995 — intervention group
Group type: COMPARATOR
Intervention: Manual BT
Number of subjects: 343
Study 28563995 — intervention group
Group type: COMPARATOR
Intervention: Manual TT
Number of subjects: 343
Study 26655398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day RS2 for 8 weeks
Number of subjects: 56
Study 26655398 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 56
Study 25694060 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin 1500 mg twice daily for 1 week
Number of subjects: 33
Study 25694060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23930213 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100-200 mg/day
Number of subjects: 150
Study 23930213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 20211108 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 14
Study 18400715 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin-enriched formula (25% of protein, glycomacropeptide 15% or 10%)
Number of subjects: 96
Study 18400715 — intervention group
Group type: COMPARATOR
Intervention: standard formula
Number of subjects: 96
Study 18400715 — intervention group
Group type: COMPARATOR
Intervention: all formula-fed infants
Number of subjects: 96
Study 18400715 — intervention group
Group type: COMPARATOR
Intervention: all groups (formula-fed)
Number of subjects: 96
Study 16845254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 3090
Study 16845254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3090
Study 12587106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern mixture model for longitudinal quality of life (QOL) data analysis
Number of subjects: 0
Study 12587106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory data techniques for longitudinal QOL data
Number of subjects: 0
Study 11020392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg per day)
Number of subjects: 185
Study 11020392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 8648286 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph interpretation with slope-mapping constraint honored (variable assigned to vertical axis)
Number of subjects: 0
Study 8648286 — intervention group
Group type: COMPARATOR
Intervention: Graph interpretation with variable not assigned to vertical axis
Number of subjects: 0
Study 8447608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine at 200 micrograms/min
Number of subjects: 52
Study 8447608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3511958 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthroom (n = 76)
Number of subjects: 148
Study 3511958 — intervention group
Group type: COMPARATOR
Intervention: Labour ward (n = 72)
Number of subjects: 148
Study 29104158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet with paricalcitol (2 μg per day)
Number of subjects: 115
Study 29104158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet with paricalcitol (2 μg per day)
Number of subjects: 115
Study 29104158 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet with placebo
Number of subjects: 115
Study 29104158 — intervention group
Group type: COMPARATOR
Intervention: High-sodium diet with placebo
Number of subjects: 115
Study 27636349 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 33
Study 27636349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 33
Study 27636349 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study 24313244 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 300 mg/day)
Number of subjects: 130
Study 24313244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 22047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment sustainers (TS)
Number of subjects: 45
Study 22047719 — intervention group
Group type: COMPARATOR
Intervention: Resumed heavy use (RHU)
Number of subjects: 45
Study 20498120 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (800/100 mg)
Number of subjects: 0
Study 20498120 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir (800/200 mg)
Number of subjects: 0
Study 19090910 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implantitis sites
Number of subjects: 15
Study 19090910 — intervention group
Group type: COMPARATOR
Intervention: Healthy sites
Number of subjects: 15
Study 15943845 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0
Study 15943845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 0
Study 15943845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone
Number of subjects: 0
Study 12600908 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg initially followed by 75 mg/d)
Number of subjects: 12562
Study 10495970 — intervention group
Group type: EXPERIMENTAL
Intervention: PCQL‐32 short form
Number of subjects: 291
Study 8901791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine intake of 45.0 mg.kg‐1.d‐1
Number of subjects: 5
Study 8901791 — intervention group
Group type: COMPARATOR
Intervention: Protein intake of 0.8 g.kg‐1.d‐1
Number of subjects: 5
Study 8901791 — intervention group
Group type: COMPARATOR
Intervention: Protein intake of 1.0 g.kg‐1.d‐1
Number of subjects: 5
Study 1807123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin prophylaxis
Number of subjects: 200
Study 1807123 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolone prophylaxis
Number of subjects: 200
Study 1807123 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotic regime
Number of subjects: 200
Study 6378045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide (200 mg daily for ten days after 24 hours of intravenous administration)
Number of subjects: 18
Study 6378045 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (3 mg/min for the first 24 hours) and Pindolol (oral for the following ten days)
Number of subjects: 18
Study 30838706 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract (BSE)
Number of subjects: 48
Study 30838706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29581124 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1488
Study 29581124 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion after EVT
Number of subjects: 1488
Study 26362167 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized daily text messaging intervention
Number of subjects: 105
Study 24014499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimic Investigatory Test Edinburgh (BITE)
Number of subjects: 0
Study 24014499 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Attitudes Test (EAT)
Number of subjects: 0
Study 22352784 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating reinforcement condition
Number of subjects: 133
Study 22352784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed reinforcement condition
Number of subjects: 133
Study 22352784 — intervention group
Group type: COMPARATOR
Intervention: Attendance control condition
Number of subjects: 133
Study 22352784 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating and fixed conditions combined
Number of subjects: 133
Study 19578224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (twice weekly)
Number of subjects: 466
Study 19578224 — intervention group
Group type: COMPARATOR
Intervention: Daily chemotherapy
Number of subjects: 466
Study 18520864 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprafascial dissection
Number of subjects: 27
Study 18520864 — intervention group
Group type: COMPARATOR
Intervention: Subfascial dissection
Number of subjects: 27
Study 18520864 — intervention group
Group type: COMPARATOR
Intervention: Deep dissection
Number of subjects: 27
Study 16105532 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Anastomosis Clip (CAC)
Number of subjects: 60
Study 16105532 — intervention group
Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 60
Study 11823073 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bolus eptifibatide 180/90 (30 min apart) and 1.33 microg/kg per min infusion with 50 mg t-PA (Group I)
Number of subjects: 649
Study 11823073 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bolus eptifibatide 180/90 (10 min apart) and 2.0 microg/kg per min infusion with 50 mg t-PA (Group II)
Number of subjects: 649
Study 10730335 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7486271 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine 0.016 mg.kg‐1
Number of subjects: 40
Study 7486271 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg.kg‐1
Number of subjects: 40
Study 2298002 — intervention group
Group type: EXPERIMENTAL
Intervention: High intravenous glucose infusion
Number of subjects: 0
Study 2298002 — intervention group
Group type: COMPARATOR
Intervention: Low intravenous glucose infusion
Number of subjects: 0
Study 2298002 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured or septic patients
Number of subjects: 0
Study 2298002 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 7459805 — intervention group
Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 716
Study 7459805 — intervention group
Group type: EXPERIMENTAL
Intervention: Halsted mastectomy with internal mammary node dissection
Number of subjects: 716
Study 30880334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg and Afatinib 30 mg
Number of subjects: 25
Study 27768508 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (n = 13)
Number of subjects: 40
Study 27768508 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n = 15)
Number of subjects: 40
Study 25943183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P1: intravenous flurbiprofen and epidural fentanyl + ketamine before surgery
Number of subjects: 100
Study 25943183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P2: intravenous flurbiprofen before surgery and epidural fentanyl + ketamine after surgery
Number of subjects: 100
Study 25943183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P3: epidural fentanyl + ketamine before surgery and intravenous flurbiprofen after surgery
Number of subjects: 100
Study 25943183 — intervention group
Group type: COMPARATOR
Intervention: Group C: normal saline treatment
Number of subjects: 100
Study 23712686 — intervention group
Group type: EXPERIMENTAL
Intervention: OA + CPM
Number of subjects: 29
Study 23712686 — intervention group
Group type: COMPARATOR
Intervention: OA
Number of subjects: 29
Study 23712686 — intervention group
Group type: COMPARATOR
Intervention: CPM
Number of subjects: 29
Study 21430514 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (vitamins E and C)
Number of subjects: 20
Study 21430514 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 20
Study 19805651 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study 16964557 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 20
Study 16964557 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 15475554 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (82.5 ± 5% of peak heart rate for 9 months)
Number of subjects: 22
Study 15475554 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 15475554 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 22
Study 11484687 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 80
Study 11484687 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic drugs
Number of subjects: 80
Study 9987256 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling and education (intervention group)
Number of subjects: 23
Study 9987256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Child Assessment Feeding Scale (NCAFS) scores (intervention group)
Number of subjects: 23
Study 7840398 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1
Study 7840398 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1
Study 7840398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (Nitrocompounds)
Number of subjects: 1
Study 7840398 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2-agonists
Number of subjects: 1
Study 7840398 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (intra-operative infusion)
Number of subjects: 1
Study 7840398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta-blockers and calcium channel blockers
Number of subjects: 1
Study 7840398 — intervention group
Group type: COMPARATOR
Intervention: Anti-platelet agents
Number of subjects: 1
Study 2742102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal detector device
Number of subjects: 100
Study 2742102 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard methods)
Number of subjects: 100
Study 4604405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous injection of 120 mg/sq m of hydrocortisone 2 hr prior to leukapheresis
Number of subjects: 22
Study 4604405 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 22
Study 29337835 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (0.3 mg/kg)
Number of subjects: 93
Study 29337835 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 93
Study 29337835 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 93
Study 30953467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy with 6 cycles of floxuridine, starting 4-12 weeks after surgery.
Number of subjects: 230
Study 30953467 — intervention group
Group type: COMPARATOR
Intervention: Resection alone (standard of care in the Netherlands).
Number of subjects: 230
Study 28219442 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg orally once daily for 24 months
Number of subjects: 11
Study 24192586 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training intervention
Number of subjects: 51
Study 24192586 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only control
Number of subjects: 51
Study 22830537 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide sandblasting followed by silorane resin composite
Number of subjects: 108
Study 22830537 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide sandblasting followed by methacrylate resin composite
Number of subjects: 108
Study 22830537 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid treatment with methacrylate resin composite
Number of subjects: 108
Study 22830537 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 108
Study 22830537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur abrasion
Number of subjects: 108
Study 22830537 — intervention group
Group type: COMPARATOR
Intervention: Control (solid resin composite)
Number of subjects: 108
Study 21508527 — intervention group
Group type: EXPERIMENTAL
Intervention: Background music
Number of subjects: 89
Study 21508527 — intervention group
Group type: COMPARATOR
Intervention: No background music
Number of subjects: 89
Study 18974713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated (HH) in warm chamber (37+/‐0.5 degrees C; RH = 70%)
Number of subjects: 10
Study 18974713 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated (EH) in warm chamber (37+/‐0.5 degrees C; RH = 70%)
Number of subjects: 10
Study 18974713 — intervention group
Group type: COMPARATOR
Intervention: Hypohydrated (HH) in room temperature (22+/‐1 degrees C; RH = 50%)
Number of subjects: 10
Study 18974713 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated (EH) in room temperature (22+/‐1 degrees C; RH = 50%)
Number of subjects: 10
Study 17488148 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 0
Study 15081457 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 200
Study 15081457 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (reduced dose)
Number of subjects: 200
Study 15081457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thalidomide)
Number of subjects: 200
Study 11876941 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (Gln) granules, 10 grams three times a day for 10 days
Number of subjects: 20
Study 11876941 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 10 grams three times a day for 10 days
Number of subjects: 20
Study 9662679 — intervention group
Group type: EXPERIMENTAL
Intervention: staff-assisted intervention
Number of subjects: 874
Study 9662679 — intervention group
Group type: EXPERIMENTAL
Intervention: staff-counseling intervention
Number of subjects: 874
Study 9662679 — intervention group
Group type: COMPARATOR
Intervention: standard care control
Number of subjects: 874
Study 7877895 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation for three months
Number of subjects: 10
Study 7877895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2908483 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 195 +/- 10 micrograms/kg/min (n = 15)
Number of subjects: 25
Study 2908483 — intervention group
Group type: COMPARATOR
Intervention: nitroprusside 1.9 +/- 0.3 micrograms/kg/min (n = 10)
Number of subjects: 25
Study 29752398 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman device implantation
Number of subjects: 1739
Study 27816856 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health and nutrition intervention with peer-led behavior change communication and health promotion through school media and health clubs.
Number of subjects: 1000
Study 27816856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1000
Study 27816856 — intervention group
Group type: COMPARATOR
Intervention: Intervention group vs Control group at midline and endline.
Number of subjects: 1000
Study 24938081 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation treatment for depression (10 sessions)
Number of subjects: 60
Study 24938081 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (10 sessions)
Number of subjects: 60
Study 23031319 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental homologous (07 V063) inactivated vaccine
Number of subjects: 0
Study 23031319 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial attenuated vaccines
Number of subjects: 0
Study 23031319 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental heterologous (LV) inactivated vaccine
Number of subjects: 0
Study 23031319 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial inactivated vaccine
Number of subjects: 0
Study 23031319 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental homologous (08 V194) inactivated vaccine
Number of subjects: 0
Study 23031319 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial attenuated vaccine
Number of subjects: 0
Study 23031319 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental heterologous (07 V063 and LV) inactivated vaccines
Number of subjects: 0
Study 20397881 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Prevention Interactive Experience (ASPIRE) intervention
Number of subjects: 1574
Study 18500375 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 18 mg
Number of subjects: 61
Study 18500375 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (10 microg/kg)
Number of subjects: 61
Study 15689862 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom bioabsorbable polymer interference screw
Number of subjects: 97
Study 15689862 — intervention group
Group type: COMPARATOR
Intervention: Titanium metal interference screw
Number of subjects: 97
Study 15689862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 12067858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 7
Study 10078857 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 85
Study 10078857 — intervention group
Group type: COMPARATOR
Intervention: No-exercise group
Number of subjects: 85
Study 7728788 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraventricular tachycardia
Number of subjects: 897
Study 7728788 — intervention group
Group type: COMPARATOR
Intervention: No supraventricular tachycardia
Number of subjects: 897
Study 7728788 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraventricular tachycardia, atrial fibrillation, advanced atrioventricular block, sinoatrial block
Number of subjects: 897
Study 2073205 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 169
Study 2073205 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 169
Study 427007 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional oxprenolol tablets
Number of subjects: 0
Study 427007 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol tablets
Number of subjects: 0